

OncoTherapy Science, Inc.

December 21, 2018

Announcement of the Initiation of Phase I Clinical Study of a Combination of OTSGC-A24 and
Immune Checkpoint Inhibitor in Patients with Gastric Cancer

OncoTherapy Science, Inc. (President & CEO: Suyoun Chung ; hereinafter, "OncoTherapy") announces that Phase I clinical study of a combination of OTSGC-A24, Nivolumab and Ipilimumab for Gastric Cancer will be initiated in NUH (National University Hospital) in Singapore. This is an investigator-initiated study, and OncoTherapy provides the study drug OTSGC-A24 as a collaborator.

This study is designed to evaluate safety, objective response as well as to evaluate an induction of peptide-specific CTL response after administration of OTSGC-A24, Nivolumab and Ipilimumab as a combination in patients with inoperable or metastatic gastric cancer.

OTSGC-A24 is the cocktail peptide vaccine product which contains multiple peptides targeting the tumor-specific antigens, highly expressed in gastric cancer cells. Each peptide contained in this cocktail is expected to induce cytotoxic T lymphocyte. Phase I clinical study of OTSGC-A24 as a single agent for refractory gastric cancer was conducted in Singapore, Korea and Japan and had been completed with favorable results on safety and immune reactivity.